Vesugen: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 24 de agosto de 2026

Vesugen is a short synthetic tripeptide (Lys-Glu-Asp, KED; CAS 204271-66-9) belonging to the family of peptide bioregulators described by the Khavinson group. In research models, its association with vascular tissue and the regulation of gene expression in endothelial cells has been explored. Material intended exclusively for research use.

Vesugen is a synthetic tripeptide with the sequence Lys-Glu-Asp (abbreviated KED), with the molecular formula C15H26N4O8, a molecular weight of 390.39 g/mol, and CAS number 204271-66-9. It is classified within the category of anti-aging compounds and, more specifically, within the family of the so-called "short peptide bioregulators" developed and studied primarily by Vladimir Khavinson's research group at the Institute of Bioregulation and Gerontology in Saint Petersburg. Like the rest of this family (for example Vilon, Epitalon, or Thymalin), Vesugen is a peptide of very low structural complexity whose conceptual premise is that short peptide fragments can interact with DNA and modulate the expression of certain genes in specific tissues. In the case of Vesugen, the target tissue proposed in this group's literature is the vascular wall and the endothelium.

From a structural standpoint, Vesugen is a linear tripeptide composed of three amino acids: lysine (Lys, K), a basic residue with a positively charged side chain; glutamic acid (Glu, E) and aspartic acid (Asp, D), both acidic residues with carboxylic side chains negatively charged at physiological pH. This combination of one positive and two negative charges confers on the molecule an amphoteric character with acidic predominance and, according to the hypotheses of the group that described it, a particular affinity for specific regions of the DNA double helix. Its small size facilitates cellular and nuclear penetration, a feature that has been invoked to explain the proposed mechanism. It should be emphasized that these structural-functional claims come mostly from a single school of research.

The proposed mechanism of action for Vesugen is fundamentally epigenetic and transcriptional. The central hypothesis of Khavinson's bioregulators holds that short peptides can bind to specific DNA promoter sequences or interact with histones, thereby modulating chromatin accessibility and the transcription rate of genes associated with the function of the target tissue. In in vitro work attributed to this group, Vesugen has been explored in cultures of vascular and endothelial cells, with the proposal that it would influence the expression of factors related to endothelial homeostasis, the synthesis of matrix components, and markers of vascular function. It is important to be transparent: the precise molecular mechanism, including the specific gene sequences supposedly modulated and the physical nature of the peptide-DNA interaction, has not been independently confirmed by external groups nor validated through reproduced clinical trials. Therefore, the mechanism should be understood as a working hypothesis supported by limited preclinical data rather than as an established mechanism.

As for documented research applications, Vesugen has been used in preclinical and laboratory studies aimed at exploring the biology of the endothelium and vascular tissue, vascular aging, and as a tool within the general line of research on peptide bioregulation of the group that described it. The reported uses fall within animal models and cell systems, not within approved clinical applications. Within this context, it has been proposed as an object of study in models of age-associated endothelial dysfunction and in work examining the hypothesis of tissue-specific gene regulation by short peptides. None of these applications amounts to a validated therapeutic use, and its interest is confined to the experimental sphere.

The level of evidence supporting Vesugen must honestly be rated as limited. Most of the published information comes from a single research group and its collaborators, and consists mainly of preclinical studies, conceptual reviews, and in vitro work. Large, randomized clinical trials replicated by independent teams that confirm both the efficacy and the proposed mechanism are lacking. This circumstance is common to the entire family of Khavinson's short peptide bioregulators and should not be interpreted as support for a therapeutic use in humans. Any reading of the available literature must take into account this single-source bias and the absence of robust external validation.

In summary, Vesugen is a short tripeptide (Lys-Glu-Asp / KED) well characterized from a chemical standpoint —with known CAS, formula, molecular weight, and sequence— but whose functional profile rests on a narrow and largely unreplicated body of evidence. Its interest to the research community lies in the possibility of studying the hypothesis of tissue-specific gene regulation by ultrashort peptides, and in particular the proposed relationship with the endothelium and vascular tissue. All the material and information presented here are for research purposes exclusively and do not constitute clinical guidance. Researchers working with this compound should handle it under standard laboratory practices and contextualize their results against the limited nature of the existing evidence.